@article{10902/12093,
year = {2017},
url = {http://hdl.handle.net/10902/12093},
abstract = {Background

Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved.


Objective

The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics.


Methods

Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors.


Results

Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (?: ?0.303, 95% confidence interval: ?0.558 to ?0.047; P = .02).


Conclusions

RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.},
organization = {This project has been supported by an unrestricted grant from Abbvie, Spain. The design, analysis, interpretation of results, and preparation of the article have been done independently of Abbvie. Dr González-Gay's studies have been supported by grants from “Fondo de Investigaciones Sanitarias” PI06/0024, PS09/00748, and PI12/00060 and RD12/0009/0013 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain).},
publisher = {Elsevier},
publisher = {Journal of Clinical Lipidology (2017), Volume 11, Issue 3, May-June 2017, Pages 749-756.e3},
title = {Lipoprotein(A) Concentrations In Rheumatoid Arthritis On Biologic Therapy: Results From The Cardiovascular In Rheumatology [Carma] Study Project},
author = {García Gómez, Carmen and Martín Martínez, Maria A. and Castañeda, Santos and Sanchez Alonso, Fernando and Uriarte Ecenarro, Miren and González Juanatey, Carlos and Romera Baures, Montserrat and Santos Rey, José and Pinto Tasende, José Antonio and Quesada Masachs, Estefanía and Tornero Molina, Jesús and Martínez González, Olga and Cobo 
Ibáñez, Tatiana and Chamizo Carmona, Eugenio and Manrique Arija, Sara and Fábregas Canales, Dolores and Díaz González, Federico and Llorca Díaz, Francisco Javier and González-Gay Mantecón, Miguel Ángel},
}